301201 誠達藥業
按盤價 
32.810 -4.280 (-11.539%)
32.810 -4.280 (-11.539%) | 2026/06 - 中期 | 2025/12 | 2024/12 | 2023/12 | 2022/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 0.110 | -0.563 | -1.272 | 4.051 | 7.762 |
| 總資產報酬率 ROA (%) | 0.098 | -0.498 | -1.149 | 3.809 | 7.087 |
| 投入資產回報率 ROIC (%) | 0.106 | -0.538 | -1.229 | 4.004 | 7.529 | 邊際利潤分析 |
| 銷售毛利率 (%) | 30.887 | 44.171 | 42.821 | 42.886 | 48.009 |
| 營業利潤率 (%) | 1.276 | -1.927 | -7.375 | 26.019 | 30.196 |
| 息稅前利潤/營業總收入 (%) | 2.274 | -3.023 | -9.372 | 23.299 | 27.876 |
| 淨利潤/營業總收入 (%) | 0.897 | -2.943 | -8.297 | 21.989 | 25.878 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | -22.540 | -37.324 | 220.512 | 60.248 | 71.297 |
| 價值變動淨收益/利潤總額(%) | 242.151 | -114.545 | -119.156 | 40.119 | 33.021 |
| 營業外收支淨額/利潤總額(%) | -52.680 | 40.962 | 9.614 | -3.404 | -3.445 | 償債能力分析 |
| 流動比率 (X) | 6.527 | 6.426 | 6.844 | 9.578 | 16.876 |
| 速動比率 (X) | 5.707 | 5.695 | 6.190 | 8.817 | 15.305 |
| 資產負債率 (%) | 10.691 | 10.759 | 11.934 | 7.185 | 4.557 |
| 帶息債務/全部投入資本 (%) | 2.217 | 3.613 | 4.608 | 1.732 | 0.077 |
| 股東權益/帶息債務 (%) | 4,386.060 | 2,661.027 | 2,066.177 | 5,660.638 | 129,661.467 |
| 股東權益/負債合計 (%) | 834.297 | 828.393 | 737.035 | 1,290.864 | 2,092.776 |
| 利息保障倍數 (X) | 1.581 | -12.551 | 7.730 | -12.503 | -21.210 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 79.397 | 89.655 | 118.494 | 100.940 | 86.132 |
| 存貨周轉天數 (天) | 160.225 | 225.090 | 251.118 | 218.244 | 219.281 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 23/09/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
